LitAlert ~~ GeneLit.com

    • Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.
    • Ibrahim EM, Refae AA, Bayer AM, Sagr ER.
    • Future Oncol. 2020 Mar 13. doi: 10.2217/fon-2020-0057. [Epub ahead of print]
    • Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    • Wolford JE, Bai J, Moore KN, Kristeleit R, Monk BJ, Tewari KS.
    • Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176-1. doi: 10.1016/j.ygyno.2020.02.030. [Epub ahead of print]
    • Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    • Liontos M, Sotiropoulou M, Kaparelou M, Tzannis K, Tsironis G, Kyriazoglou, Tsiara A, Zakopoulou R, Koutsoukos K, Zagouri F, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Bamias A.
    • Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224-9. doi: 10.1016/j.ygyno.2020.03.008. [Epub ahead of print]